

Accomplished professional with diverse experience poised to transition solid background in medical and strategic clinical affairs to excel in a future executive leadership position within the pharmaceutical industry. Offers team leadership, external personnel management, and conflict resolution skills. Exceptionally organized, disciplined and self-motivated; possess well-developed interpersonal skills and the ability to motivate and direct others in a supportive and relax team environment. Business administration experience: coordination with internal and internal customers, cross-functional teams and vendors in the execution of daily task and functions. Demonstrate excellent track record of deliverables.

PROFESSIONAL EXPERIENCE

Sanofi – Paris, France, May 2010 – Present

Global Medical Affairs: Medical Director – Diabetes Metabolism Franchise

Development and execution of Global Medical Affairs strategies and tactics within the international diabetes insulin franchise with main responsibilities in product planning and Life Cycle Management on the impact of line extensions, new indications, formula changes, thought leader development and publication strategies for Lantus (insulin glargine) and Apidra (glulisine). Lead the global sanofi data analytics (SADA) and ORIGIN taskforce to design and implement global diabetes data mining studies and support on-going and new study registries, and randomized clinical trials for insulin glargine. Develop and maintain close professional relationships with global Key Thought Leaders (physicians and researchers) within pertinent global medical community with the goal to increase external collaborative opportunities to ensure successful and appropriate execution of studies and data publication and dissemination. Build long-term analysis plan and work with countries to ensure timely publication of local data. Work with global R&D and trial investigators to develop medical communication plan for all Lantus and Lantus CV platform trials.

Sanofi-Aventis – Bridgewater, New Jersey, August 2008 – June 2010

U.S. Medical Affairs: Medical Director / Scientific Officer

Serve as the U.S. medical affair leader in the implementation and execution of Avapro/Avalide/Plavix medical and business strategies that support the U.S. brand imperatives. This requires alignment of initiatives across existing Joint Ventures with Bristol-Myers Squibb company, including design and execution of all strategies and programs, review of consumer and professional promotional materials for medical and scientific content in compliance with corporate standards and government/industry regulations, and development of current and on-going medical strategy and tactical plans. In addition, when appropriate, support Sales, Marketing and Legal functions on marketed products and cardiovascular drugs currently in development portfolio, provide medical support to product planning and Life Cycle Management groups on the impact of line extensions, new indications, formula changes, opinion leader development and publication strategies, and work with global medical affairs and brand team to ensure strategic and tactical alignment.

Sanofi-Aventis – Bridgewater, New Jersey, January 2006 – August 2008

U.S. Medical Education: Senior Manager

Implement medical education projects based on adult-learning principles that effectively translate current venous thromboembolic disease (VTE) clinical practices and guidelines into effective medical education. This include development of appropriate VTE educational strategies using key clinical/scientific information that align with U.S. medical affairs and brand objectives, management of medical communication agencies and budgets for assigned projects, understanding of current ACME, FDA, AMA, OIG, and PhRMA guidelines, and working with key VTE medical leaders to develop programs that address unmet clinical and scientific needs within the medical community.

Sanofi-Synthelabo – San Diego, California, April 2004 – December 2005

U.S. Medical Affairs: Regional Medical Manager

Establish and maintain credible peer-to-peer scientific relationships with international, national, and top regional opinion leaders and serve as a primary resource for cardiovascular clinical and scientific information to internal associates and external Health Care providers on CV products (Plavix, Avapro/Avalide, Lovenox) via development of strategic partnerships. Provide input in the development of and ensure the appropriate execution of clinically relevant regional medical meetings (e.g. advisory boards, symposia, consultant and investigator meetings). Assist in the identification of Investigators and sites for company trial and serve as a liaison for the review, submission, execution and completion of Investigator Initiated Trial proposals.

University of Pittsburgh School of Medicine – Pittsburgh, Pennsylvania, January 2004 – April 2004

Postdoctoral Fellow with Professor Gerard L. Apodaca

Examine the mechanism of pressure-induced membrane traffic in specialized epithelial cells (umbrella cells) that line the nephrons of the kidney and the inner surface of the urinary bladder. Understand how umbrella cells sense changes in stretch, and

how these changes are translated through secondary messenger cascades into vesicle fusion events along with membrane recovery through endocytosis.

EDUCATION

University of Pittsburgh School of Medicine – Pittsburgh, Pennsylvania

Ph.D. in Cell Biology & Physiology, January 2004

Thesis in Cell Biology & Electrophysiology under Professor Gerard L. Apodaca

Title: "Pressure-Regulated Membrane Traffic and Ion Transport in Urinary Bladder Epithelium"

University of Washington – Seattle, Washington

B.S. in Microbiology, May 1997

RECOGNITION AND AWARDS

2012 Sanofi Top Employee Rating (8 of 9)	03/2012
2011 Sanofi-Aventis Employee Rating >90 th Percentile	03/2011
2010 Sanofi-Aventis Employee Rating >90 th Percentile	03/2010
2008 Invited to the 2008 Venous Disease Coalition Annual Meeting / U.S. Surgeon General Call-To-Action Announcement	08/2008
2007 Sanofi-Aventis Employee Rating – Exceed (highest possible)	03/2008
2005 Sanofi-Synthelabo/Sanofi-Aventis Employee Rating – Exceed (highest possible)	03/2006
2005 Sanofi-Synthelabo/Sanofi-Aventis CV/Thrombosis Medical Affairs Special Award	07/2005
University of Pittsburgh School of Medicine Histology Teaching Fellowship	06/2000 – 01/2004

LANGUAGE PROFICIENCIES

English:	Native Language
Mandarin:	Fluent
Taiwanese:	Fluent

PEER-REVIEWED PUBLICATIONS

1. Jarvis MA, Wang E, Meyers HL, Smith PP, Corless CL, Henderson GJ, Vieira J, Britt WJ, Nelson JA Human cytomegalovirus infection of Caco-2 cells occurs at the basolateral membrane and is differentiation state dependent. *Journal of Virology*. 73: 4552-4560, **1999**.
2. Birder LA, Nealen M, Kiss S, deGroat WC, Caterina MJ, Wang E, Apodaca G, Kanai AJ. β -Adrenergic Agonists Stimulate Endothelial Nitric Oxide Synthase in Rat Urinary Bladder Urothelial Cells. *Journal of Neuroscience*. 22: 8063-8070, **2002**.
3. Birder LA, Nakamura Y, Kiss S, Nealan ML, Barrick S, Kanai AJ, Wang E, Ruiz G, deGroat WC, Apodaca G, Watkins S, Caterina J. Altered bladder function in mice lacking the vanilloid receptor TRPV1. *Nature Neuroscience*. 5: 856-860, **2002**.
4. Truschel ST*, Wang E*, Ruiz WG, Leung S-M, Rojas R, Lavelle J, Zeidel M, Stoffer D, Apodaca G. Stretch-regulated exocytosis/endocytosis in bladder umbrella cells. *Molecular Biology of the Cell*. 13: 830-846, **2002**.
**The first two authors contributed equally and are listed in no particular order.*
5. Wang E, Truschel S, Apodaca G. Analysis of hydrostatic pressure-induced changes in umbrella cell surface area. *Methods*, 30: 207-217, **2003**.
6. Wang E, Lee JM, Johnson JP, Kleyman T, Bridges R, Apodaca G. Hydrostatic pressure-regulated ion transport in bladder uroepithelium. *American Journal of Physiology – Renal Physiology*. 285(4): F651-F663, **2003**.
7. Archaya P, Beckel J, Ruiz W, Wang E, Rojas R, Birder L, Apodaca G. Distribution of the tight junction proteins ZO-1, occludin, and claudin-4, -8, and -12 in bladder epithelium. *American Journal of Physiology – Renal Physiology*. 287(2): F305-318, **2004**.
8. Wang E, Lee JM, Ruiz WG, Balestreire E, Bodungen M, Barrick S, Cockayne D, Birder L, Apodaca G. ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells. *Journal of Clinical Investigation*. 115: 2412-2422, **2005**.
9. Aschner P, Chan J, Owens D, Picard S, Wang E, Dain MP, Pilorget V, Echtay A, Fonseca V. Evaluation of insulin glargine vs sitagliptin in insulin-naïve patients (EASIE) with type 2 diabetes mellitus (T2DM) uncontrolled on metformin: a multicentre, randomized trial. (**Accepted to LANCET Journal**).
10. Lepercq J, Lin J, Hall G, Wang E, Dain MP, Riddle M, Home P. Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine vs NPH insulin during pregnancy. (**Accepted to Obstetrics and Gynecology International**).

11. Freemantle N, Balkau B, Danchin N, Wang E, Marre M, Vespasiani G, Kawamori R, Home PD. Factors influencing initial choice of insulin therapy in a large international non-interventional study in people with type 2 diabetes. (**Accepted to Diabetes, Obesity and Metabolism**).
12. Dailey G, Wang E. Does insulin glargine influence cardiovascular outcomes in patients with type 2 diabetes? *In preparation*.
13. Simon ACR, Bolli GB, Wang E, Holleman F. Clinical contributors to differences in final basal insulin dose in type 2 diabetes mellitus, with a special focus on BMI. *In preparation*.
14. Hall GC, McMahon AD, Dain MP, Wang E, Home P. Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin therapy in the UK. *In preparation for Diabetes Medicine*.
15. Ram CV, Wang E, Neutel J. Angiotensin receptor blockers versus ACE inhibitors in the treatment of hypertension: medical and cost perspectives. *In preparation*.

ABSTRACT PRESENTATIONS

1. Wang EC, Bridges R, Johnson J, Apodaca G. Stretch-induced increases in luminal surface area of uroepithelium may involve activation of mechanosensitive ion channels. *Molecular Biology of the Cell*. 9:466a, **1998**.
2. Wang EC, Truschel ST, Ruiz WG, Apodaca G. Stretch-induced increases in luminal surface area of uroepithelium may involve mechanosensitive ion channel activity. *Molecular Biology of the Cell*. 10:227a, **1999**.
3. Truschel S, Wang E, Ruiz WG, Apodaca G. Stretch-induced changes in urinary bladder epithelium. *Molecular Biology of the Cell*. 10:398a, **1999**.
4. Truschel ST, Wang EC, Ruiz WG, Stoffer DS, Zeidel ML, Apodaca G. Stretch-mediated exocytosis of discoidal vesicles in urinary bladder epithelium. *Molecular Biology of the Cell*. 11:497a, **2000**.
5. Wang EC, Truschel ST, Apodaca G. Stretch-induced increases in apical surface area of bladder umbrella cells is via a cAMP, PKA-dependent mechanism. *Molecular Biology of the Cell*. 12:212a, **2001**.*
6. Truschel ST, Wang E, Ruiz W, Apodaca G. Stretch-mediated exocytosis/endocytosis in urinary bladder epithelium. *Molecular Biology of the Cell*. 12:212a, **2001**.*
7. Wang EC, Truschel ST, Lee JM, Apodaca G. Stretch-induced increases in apical surface area of bladder umbrella cells are modulated by purinergic receptors, cAMP and PKA-dependent mechanism. *Molecular Biology of the Cell*, 13: 507a, **2002**.
8. Truschel ST, Ruiz W, Guerriero C, Wang E, Apodaca G. Stretch-mediated changes in urinary bladder epithelium. *Molecular Biology of the Cell*, 13: 507a, **2002**.
9. Wang EC, Lee JM, Apodaca G. Pressure-induced exocytosis in bladder umbrella cells is dependent on ATP release and purinergic signaling. *Molecular Biology of the Cell*, 14: 355a, **2003**.
10. Yu W, Wang EC, Apodaca G. Adenosine receptor-dependent modulation of bladder umbrella cell surface area. *Molecular Biology of the Cell*, 14: 355a, **2003**.
11. Cantrell S, Hofer K, Muszka J, Wang E. A stepwise, systematic approach to a CE initiative. 33rd (**2008**) Annual Alliance for Continuing Medical Education Conference, Orlando, FL.
12. Hofer K, Cantrell S, Muszka J, Wang E. A Bridge to learning: Development and implementation of an on-line self-assessment tool. 34th (**2009**) Annual Alliance for Continuing Medical Education Conference, San Francisco, CA.
13. Jones E, Wang E. Optimizing travel across the organization: Extension of a project in IME and CVT. 1st (**2010**) Annual Sanofi-Aventis U.S. Medical Affairs Scientific Congress, Bridgewater, NJ.
Recognized as one of the top innovative posters.
14. Wang E, Zak C. An innovative and collaborative process to understand future primary care model. 1st (**2010**) Annual Sanofi-Aventis U.S. Medical Affairs Scientific Congress, Bridgewater, NJ.
15. Home P, Wang E, M Marre. Baseline risk factors for weight gain in people with type 2 diabetes mellitus beginning insulin therapy in the CREDIT study. 71th (**2011**) American Diabetes Association, San Diego, CA (*Publication only*).
16. Tsai ST, Wang E, Ji L. First basal insulin evaluation in Asia (FINE Asia) study: baseline characteristics of the study population. 71th (**2011**) American Diabetes Association, San Diego, CA (*Poster*).
17. Ji L, Wang E, Tsai ST. National differences in glycemic control 3 and 6 months after initiation of basal insulin in patients with type 2 diabetes: a subanalysis of the FINE-Asia database. 71th (**2011**) American Diabetes Association, San Diego, CA (*Poster*).
18. Ji L, Wang E, Tsai ST. Factors associated with A1c reduction in Asian patients with T2DM: an analysis of the FINE Asia registry. 71th (**2011**) American Diabetes Association, San Diego, CA (*Publication only*).

19. Tsai ST, Wang E, Ji L. Factors associated with insulin dose change in Asian patients with T2DM: An analysis of the FINE Asia registry. 71th (2011) American Diabetes Association, San Diego, CA (*Publication only*).
20. Holleman F, Wang E, Bolli G. Detemir is associated with a higher insulin dose compared to insulin glargine across a wide BMI-range. 71th (2011) American Diabetes Association, San Diego, CA (*Poster*).
21. Balkau B, Home P, Wang E, Marre P. Factors associated with weight gain in type 2 diabetes patients starting on insulin: The CREDIT study. 47th (2011) European Association for the Study of Diabetes, Lisbon, Portugal (*Oral presentation*).
22. Suastika K, Tsai ST, Wang J, Tan K, Wang E, Lin J, Ji L. Baseline characteristics of the first basal insulin evaluation in Asia (FINE-Asia) study population. 47th (2011) European Association for the Study of Diabetes, Lisbon, Portugal (*Poster*).
23. Wang J, Ji L, Suastika K, Tan K, Wang E, Lin J, Tsai ST. Initiation of basal insulin in patients with type 2 diabetes: National differences in glycaemic control after 6 months in a subanalysis of the FINE Asia database. 47th (2011) European Association for the Study of Diabetes, Lisbon, Portugal (*Poster*).
24. Ji L, Suastika K, Wang J, Tan K, Wang E, Lin J, Tsai ST. Factors associated with HbA1c reduction in Asian patients with T2DM: An analysis of the FINE Asia registry. 47th (2011) European Association for the Study of Diabetes, Lisbon, Portugal (*Poster*).
25. Wang E, Lin J, Dailey G. Differences in glycaemic reductions between insulin therapies according to body mass index: pooled results from clinical trials. 47th (2011) European Association for the Study of Diabetes, Lisbon, Portugal (*Poster*).
26. Tsai ST, Wang E, Lin J, Ji L. Differences in Dose, HbA1c, and hypoglycemia between insulin therapies according to BMI: A FINE Asia subanalysis. (2011) International Diabetes Federation, Dubai, United Arab Emirates (*Poster*).
27. Ji L, Wang E, Lin J, Tsai ST. Variation of patient comorbidities with duration of type 2 diabetes in Asian patients: analysis of the FINE Asia registry. (2011) International Diabetes Federation, Dubai, United Arab Emirates (*Poster*).
28. Little S, Wang E, Lin J, Home P, Shaw J. Glycaemic control and hypoglycaemia prevalence with insulin glargine versus NPH insulin according to BMI: An analysis of pooled RCT data. (2011) International Diabetes Federation, Dubai, United Arab Emirates (*Poster*).
29. Lankisch MR, Owens DR, Wang E, Lin J, Del Prato S. Dose change in a basal-plus regimen of insulins glargine and glulisine across BMI groups. (2011) International Diabetes Federation, Dubai, United Arab Emirates (*Poster*).
30. Hall GC, McMahon AD, Dain MP, Wang E, Home P. GIP-1 receptor agonist (GLP1ra) and insulin efficacy in primary health care. (2012) American Diabetes Association, Philadelphia, PA (*Poster*).
31. Owens DR, Del Prato S, Lin J, Wang E, Lankisch M. Impact of diabetes duration on efficacy and safety of a basal-plus regimen of insulin glargine plus once daily insulin glulisine: a pooled analysis from 4 clinical trials. (2012) American Diabetes Association, Philadelphia, PA (*Publication only*).
32. Lankisch MR, Owens DR, Wang E, Lin J, Del Prato S. Basal-plus regimen of insulin glargine and glulisine is weight neutral across BMI groups. (2012) American Diabetes Association, Philadelphia, PA (*Publication only*).
33. Odawara M, Wang E, Lin J, Admane K, Ito T, Kadowaki T. Glycemic control and hypoglycemia prevalence in Japanese participants with type 2 diabetes according to BMI: a sub-analysis of the ALOHA data. (2012) American Diabetes Association, Philadelphia, PA (*Poster*).
34. Dailey G, Lin J, Wang E. Efficacy and safety of a basal-bolus regimen of basal insulin plus insulin glulisine in patients with type 2 diabetes: a pooled analysis of 5 clinical trials. (2012) American Diabetes Association, Philadelphia, PA (*Poster*).
35. Del Prato S, Lankisch M, Lin J, Wang E, Owens DR. Efficacy and safety of a basal-plus regimen of insulin glargine plus insulin glulisine in patients with type 2 diabetes: a pooled analysis of 4 clinical trials. (2012) American Diabetes Association, Philadelphia, PA (*Poster*).
36. Chase P, Lin J, Wang E, Garg S. Treatment of people with type 1 diabetes in the US: the Impact database. (2012) American Diabetes Association, Philadelphia, PA (*Poster*).
37. Garg S, Lin J, Wang E, Chase P. Evaluating overall glycaemic management of people with type 1 diabetes in the US. (2012) American Diabetes Association, Philadelphia, PA (*Publication only*).
38. Kautzky-Wiler A, Kosi L, Mihaljevic R, Lin J, Wang E. Glycemic control and hypoglycemia prevalence according to gender: an analysis of RCT data. (2012) American Diabetes Association, Philadelphia, PA (*Poster*).
39. Fanelli CG, Porcellati F, Lin J, Wang E, Lucidi P, Bolli GB. Glycemic control and hypoglycemia prevalence according to BMI: an analysis of RCT data. (2012) American Diabetes Association, Philadelphia, PA (*Publication only*).
40. Lucidi P, Porcellati F, Lin J, Wang E, Bolli GB, Fanelli CG. Efficacy and safety of insulin glargine vs NPH insulin in subjects with type 2 diabetes mellitus uncontrolled on oral agents: a pooled analysis of RCT data. (2012) American Diabetes Association, Philadelphia, PA (*Poster*).

41. Little S, Wang E, Lin J, Home P, Shaw J. Factors influencing prevalence of hypoglycemia in RCTs of previously insulin-naïve people with type 2 diabetes. (2012) American Diabetes Association, Philadelphia, PA (*Publication only*).
42. Raccach, D, Lin J, Bahloul A, Wang E, Penforinis A. Meta-analysis of efficacy and safety outcomes associated with the basal-plus regimen of insulin glargine and insulin glulisine among type 2 diabetes patients with HbA1c≥8%. (2012) American Diabetes Association, Philadelphia, PA (*Publication only*).
43. Javaz S, Soewondo P, Wang E, Admane K. PERSISTence on Glimepiride-metformin (Amaryl M) fixed combination in everyday practice in Asian type 2 diabetes patients. (2012) American Diabetes Association, Philadelphia, PA (*Poster*).
44. Jasul GV, Wang CY, Wang E, Admane K. Effect of insulin switching on A1c in inadequately controlled Asia Pacific diabetes patients. (2012) American Diabetes Association, Philadelphia, PA (*Publication only*).
45. Wang E, Lin J, Cali A, Dailey G. Efficacy and safety of a basal-bolus regimen of basal insulin plus insulin glulisine in patients with type 2 diabetes: a pooled analysis of 5 clinical trials. *Submitted to 2012 EASD*.
46. Dailey G, Lin J, Wang E, Cali A. Pooled analysis of clinical trials of a basal-bolus regimen of basal insulin plus insulin glulisine in patients with type 2 diabetes stratified by BMI. *Submitted to 2012 EASD*.
47. Cali A, Dailey G, Lin J, Wang E. A pooled analysis of patients with type 2 diabetes mellitus to evaluate the efficacy and safety of a basal-bolus regimen across different age groups. *Submitted to 2012 EASD*.
48. Ji L, Admane K, Lin J, Shang SH, Wang E. Initiation of basal insulin in Chinese patients with type 2 diabetes: an analysis of the FINE Asia registry. *Submitted to 2012 EASD*.
49. Admane K, Pan C, Ning G, Zhang Q, Lin J, Wang E. Pooled clinical trial analysis of insulin glargine vs. NPH in Asian insulin-naïve patients with type 2 diabetes. *Submitted to 2012 EASD*.
50. Wang J, Ji L, Shang SH, Wang E, Lin J, Admane K. Glycemic control and hypoglycemia prevalence in Chinese T2DM patients treated with insulin glargine or NPH: an analysis of the FINE Asia registry population. *Submitted to 2012 EASD*.
51. Bolli GB, Francesca P, Lin J, Cali A, Wang E, Dain MP, Lucidi P, Fanelli CG. Reduction in HbA1c and hypoglycemia rates with insulin glargine vs NPH in treatment-naïve patients with Type 2 diabetes stratified by BMI: Pooled analysis of 6 clinical trials. *Submitted to 2012 EASD*.
52. Garg S, Wang E, Cali A, Dain MP, Lin J, Chase P. Glycemic control and safety of insulin glargine among T1D patients in the United States: an analysis of the IMPACT database. *Submitted to 2012 EASD*.
53. Aschner P, Chan J, Owens D, Picard S, Wang E, Dain MP, Pilorget V, Ehtay A, Fonseca V. Triple combination of insulin glargine, sitagliptin and metformin improves glycemic control in patients with type 2 diabetes mellitus (T2DM): The EASIE extension trial. *Submitted to 2012 EASD*.
54. Fanelli C, Porcellati F, Lin J, Wang E, Dain MP, Lucidi P, Bolli GB. Glycemic control and hypoglycaemic prevalence according to BMI: an analysis of randomised, controlled trial data. *Submitted to 2012 EASD*.
55. Kautzky-Willer A, Kosi L, Mihaljevic R, Dain MP, Lin J, Wang E. Glycaemic control and hypoglycaemia prevalence according to gender: an analysis of randomized, controlled trial data. *Submitted to 2012 EASD*.
56. Chase P, Wang E, Cali A, Dain MP, Lin J, Garg S. Glycaemic control and safety of insulin glargine among type 1 diabetes patients in the United States: an analysis of the IMPACT database. *Submitted to 2012 EASD*.
57. Wang CH, Soegondo S, Wang E, Admane K. Patient and physician satisfaction with Lantus SoloSTAR in Asia Pacific. *Submitted to 2012 EASD*.
58. Jasul Jr GV, Wang CY, Wang E, Admane K. Effect of insulin switching on A1c in inadequately controlled Asian pacific diabetes patients. *Submitted to 2012 EASD*.
59. Javaz SA, Soewondo P, Wang E, Admane K. PERSISTence on glimepiride-metformin (Amaryl M) fixed combination in everyday practice in Asian type 2 diabetes patients. *Submitted to 2012 EASD*.

**Abstracts 5 and 6 were chosen to be included in the 2001 American Society of Cell Biology Pressbook for wide scientific appeal (Brochure reprint available upon request).*

ORAL PRESENTATIONS

1. **2002.** Invited speaker at the 2002 Local Traffic Conference, "Pressure-induced membrane traffic in bladder umbrella cells." University of Pittsburgh, Pittsburgh, PA
2. **2003.** Invited post-doctoral candidate speaker, "ATP and P2X receptor dependent membrane traffic in urinary bladder epithelium." Roche Biosciences, Palo Alto, CA
3. **2008.** Invited speaker at the 2008 Medical Education Congress, "Maximizing your 2008 medical education: effective design, evaluation, and meaningful outcome." May 7-9, Loews Philadelphia Hotel, Philadelphia, PA

4. **2008.** Invited speaker at the 2008 3rd Annual Pharmaceutical & Medical Device CME Conference, "Cooperation, Support & Responsibility - Facilitating Multi-Supported Grants." Oct 6-7, Park Hyatt Philadelphia at the Bellevue, Philadelphia, PA (*Invitation declined due to internal s-a promotion and transfer to medical affairs*)
5. **2009.** Accepted for oral breakout session presentation at the Alliance for Continuing Medical Education 34th Annual Conference, "Tracking Learning in Real Time: Designing CME for Immediate Results." Jan 28-31, San Francisco Marriott, San Francisco, CA
6. **2009.** Invited distinguished speaker at the 4th Annual Forum on Educational Grants for the Bio/Pharmaceutical Industry, "Adhere to Regulations and Guidelines, Improve Review Collaboration and Ensure Transparency for Funding Medical Education Programs." Sept 14-15, Crown Plaza Philadelphia Downtown, Philadelphia, PA
7. **2011.** Invited speaker at the 2011 2nd Annual Meeting on Commercialization Strategies and Market Access for Personalized Medicines & Companion Diagnostics, "An Innovative and Collaborative Process to Understand the Future Primary Care Model and Strategic Opportunities." February 10, Miami, FL
8. **2011.** Invited speaker at the 2011 CBI's 3rd Annual Forum on Speaker Program Management, "Co-Marketing Products - Explore Joint Ventures in Speaker Programs." February 24-25, Philadelphia, PA (*Invitation declined due to schedule conflict*)

REFERENCES

<http://www.linkedin.com/pub/edward-wang/3/940/226> and also available Upon Request